Srinivas Akkaraju bought $5.0M of KLRS
director, owner at Allovir, Inc.. 479,847 shares at an average of $10.42, traded Dec 18, 2025, filed Feb 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$5.0M at market
- +6Relative to holdingsHoldings up 32%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.6%, 3m -43.1%, 6m -51.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000166, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2025 | POpen-market purchase Common Stockindirect: By Samsara Opportunity Fund, L.P. | +479,847 | $10.42 | $5.0M | 1,979,847 | Feb 17, 2026 |
Related signals
Other insiders at Allovir, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | KLRSbuy Allovir, Inc. | Srinivas Akkaraju director, owner | $1.2M 244,300 shares | +12% | |
| 35Weak | KLRSsell Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $13k 1,915 shares | -100% | |
| 25Weak | KLRSsell Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $8,135 907 shares | -32% | |
| 30Weak | Allovir, Inc. | Edward Miller General Counsel | $1,068 106 shares | -2% | |
| 30Weak | Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $967 96 shares | -3% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $3,053 303 shares | -1% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $1,226 129 shares | -0% | |
| 30Weak | Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $342 36 shares | -1% | |
| 30Weak | Allovir, Inc. | Edward Miller General Counsel | $494 52 shares | -1% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $431 979 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.